Devonian Health Group Inc.

Devonian Health Group Inc. is a Canadian clinical-stage pharmaceutical company headquartered in Montmagny, Québec, specializing in the development of drugs for a range of autoimmune and fibroinflammatory conditions. Incorporated in 2015, the company's mission is to translate scientific research into innovative and effective therapeutic solutions to improve patients' quality of life globally, focusing on addressing unmet medical needs through ethical, safe, and efficacious treatments.

The company's core strategy involves developing prescription botanical drugs, leveraging its proprietary Supra Molecular Complexes Extraction and Stabilization Technology (SUPREX™) platform. Its flagship product, Thykamine™, is under development for conditions such as ulcerative colitis, atopic dermatitis/eczema, and psoriasis, demonstrating anti-inflammatory, antioxidant, and immunomodulatory activities. Devonian also develops high-value cosmeceutical products, including the Purgenesis™ anti-aging line and the R-Spinasome® active ingredient. Additionally, the company operates a drug distribution division, Altius Healthcare Group LP, which sells prescription pharmaceutical products in Canada under license from brand-name companies.

Recent developments include the appointment of Dennis Turpin as Chief Financial Officer in February 2026 and the election of new directors at its Annual General and Special Meeting in March 2026. The company completed a reverse stock split (consolidation) on January 22, 2026, to potentially broaden its investor base and meet U.S. stock exchange listing requirements. Devonian reported positive preclinical results for Thykamine™ in lung fibrosis and additional molecular data from a MASH liver study in February 2026. The company faced a cease trade order in April 2025 due to delayed financial filings but continues to advance its pipeline, with Dr. André P. Boulet serving as Chairman and CEO.